Myriad Genetics Stock Sees Significant Activity This Week

Highlights

• Graham Capital Management acquires shares of Myriad Genetics.
• Multiple firms have adjusted stakes in Myriad Genetics this quarter.
• Consensus rating for MYGN remains neutral among several research firms.

Myriad Genetics, Inc. (NASDAQ:MYGN) is a molecular diagnostics company specializing in genetic testing and precision medicine solutions. The company recently witnessed stake adjustments by several major firms. According to the latest 13F filing, Graham Capital Management L.P. acquired shares of Myriad Genetics during the first quarter. The total position represents a small fraction of the company's total shares outstanding. This addition signifies one of multiple movements in MYGN’s structure.

Other firms have also altered positions in the company’s stock. Nuveen LLC recorded a new position in the first quarter, representing a notable engagement with MYGN. D. E. Shaw & Co. Inc. increased its holdings substantially in the fourth quarter, now owning a large block of shares following the acquisition of additional units. Connor Clark & Lunn Management Ltd. also reported growth in its stake,additional shares during the first quarter. Walleye Capital LLC entered a new position, while Knott David M Jr similarly acquired shares within the same period. Collectively, hedge funds and institutional entities control the overwhelming majority of MYGN’s stock.

These transactions illustrate dynamic adjustments among firms, reflecting changes in concentration and portfolio allocations. Myriad Genetics’ corporate structure is influenced by multiple entities managing significant portions of the stock, contributing to a tightly monitored share environment.

How do market ratings influence Myriad Genetics activity?

Myriad Genetics (NASDAQ:MYGN) has been subject to evaluations from several research firms. These evaluations provide updates on perceived market performance relative to sector trends. For example, Scotiabank revised its assessment of the company from a sector-outperform rating to a sector-perform designation. This change included an adjustment to the target value originally assigned to the stock. Piper Sandler similarly reduced its target estimate while maintaining an overweight classification in the context of their evaluation methodology.

Data compiled from various research entities shows that MYGN currently has a consensus rating of “Hold.” Ratings are distributed with multiple firms assigning a equivalent, several applying Hold, and one assigning Sell. The overall assessment does not favor aggressive positioning, highlighting the current neutral stance among market watchers. Price targets for MYGN have been adjusted downward by some firms in light of market performance and company-specific developments.

Which firms recently increased Myriad Genetics exposure?

Several entities increased exposure to MYGN in recent reporting periods. D. E. Shaw & Co. Inc. stands out as one of the largest holders, adding a substantial number of shares during the fourth quarter. This significant increase reflects a deliberate adjustment in their existing stake. Connor Clark & Lunn Investment Management Ltd. augmented its exposure through a first-quarter transaction, expanding the number of shares held.

Graham Capital Management L.P., while smaller in proportion, also acquired a block of MYGN shares in the first quarter, reinforcing the trend of active adjustments in the company's share. Walleye Capital LLC and Knott David M Jr entered positions for the first time during this period. These movements indicate that MYGN continues to be monitored closely by major market participants, with positions shifting according to broader portfolio considerations.

What percentage of Myriad Genetics shares are controlled?

Hedge funds and other large entities collectively manage the vast majority of shares in Myriad Genetics (NASDAQ:MYGN). According to filings, over ninety-nine percent of shares are concentrated within this group. This high concentration underscores the company’s stock as being largely in the hands of structured market participants rather than dispersed among individual traders.

This concentration has implications for share liquidity and market dynamics. Adjustments by any of these major stakeholders can influence price trends, trading volumes, and general stock activity. MYGN’s market environment is therefore shaped significantly by institutional decisions and the timing of their share acquisitions or reductions.

Which firms reduced Myriad Genetics positions recently?

Some firms have modified their positions by reducing exposure to MYGN shares. Adjustments can include partial divestments or realignments in portfolio allocation. The reported data shows that in addition to additions, certain firms have curtailed positions, reflecting rebalancing activity. Specific quantities and timing of these reductions contribute to overall market movement, affecting how shares are distributed among entities.

Nuveen LLC, for instance, engaged with the stock by initiating a new position rather than reducing, while other entities followed strategies that included scaling existing stakes. Overall, the balance of additions and reductions contributes to the stability of MYGN’s market profile.

How frequently are Myriad Genetics shares adjusted quarterly?

The first quarter of the fiscal year has been active for MYGN share adjustments. Multiple transactions were recorded across different firms, encompassing both new entries and expanded positions. D. E. Shaw & Co. Inc. recorded significant additions in the fourth quarter, while the first quarter saw several entities, including Graham Capital Management L.P. and Connor Clark & Lunn Investment Management Ltd., actively acquiring additional shares.

Quarterly filings provide insights into the magnitude and timing of these adjustments. By observing the quarterly activity, it becomes clear that Myriad Genetics’ stock is closely tracked, with shifts occurring on a regular basis as portfolio strategies evolve.

What research firms monitor Myriad Genetics developments?

A range of research firms provides ongoing coverage of MYGN, offering updates on market performance, target values, and sector positioning. Scotiabank and Piper Sandler are among the prominent firms contributing assessments that reflect current market conditions. These evaluations can include revisions to classifications, target adjustments, and changes in comparative rankings within the biotechnology and diagnostics sector.

Four research entities currently assign a equivalent rating, nine assign Hold, and one assigns Sell, collectively indicating a majority of neutral positions. Target value adjustments by these firms align with observed market movements and overall trading activity, shaping the broader perception of MYGN in the public market space.

How do acquisitions impact Myriad Genetics market?

Acquisitions of MYGN shares by firms such as Graham Capital Management L.P. and others can influence the company’s market profile. While the shares acquired are a small fraction of total outstanding shares, the transactions signal active engagement by multiple entities. The presence of large-scale stakeholders maintaining positions can contribute to stability and provide visibility into market behavior surrounding the stock.

Recent acquisitions, including those by Connor Clark & Lunn Investment Management Ltd. and Walleye Capital LLC, reflect ongoing activity. These moves are carefully recorded in regulatory filings and can be analyzed to understand trends in share distribution and concentration over time.

Which firms recently increased Myriad Genetics positions significantly?

Myriad Genetics, Inc. has seen multiple entities expand positions in recent reporting periods. D. E. Shaw & Co. Inc. notably increased holdings in the fourth quarter, acquiring additional shares to grow an already substantial block. This move demonstrates active adjustments to the firm’s engagement with the stock.

Connor Clark & Lunn Investment Management Ltd. added shares in the first quarter, expanding the size of its stake. Graham Capital Management L.P. initiated a new position during the same period. Walleye Capital LLC also recorded a new stake, marking entry into the company’s share structure. Knott David M Jr acquired shares in the first quarter, further contributing to dynamic activity. These additions illustrate the ongoing attention MYGN receives from major stakeholders.

How do quarterly adjustments impact Myriad Genetics?

Quarterly filings provide detailed insights into the distribution of Myriad Genetics (NASDAQ:MYGN) shares. The first quarter recorded multiple acquisitions, including new entries and expansions by existing holders. These adjustments influence the concentration of shares and reflect strategic considerations by participating entities.

High concentration of by large entities means that even small adjustments can influence the composition of market-held shares. The collective activity in a single quarter demonstrates the dynamic nature of MYGN’s share profile and the role of structured stakeholders in shaping the trading environment.

What percentage of Myriad Genetics shares are highly concentrated?

Hedge funds and other major firms maintain control over the majority of Myriad Genetics shares. Reports indicate that over ninety-nine percent of the company’s stock is managed by such entities. This concentration emphasizes a controlled market presence, where relatively few participants dominate the distribution of shares.

The concentrated structure affects market behavior, liquidity, and price movement patterns. As these stakeholders adjust positions, the resulting activity can create shifts in trading volumes and influence broader perception in the market.

Which entities entered Myriad Genetics positions first quarter?

Graham Capital Management L.P., Walleye Capital LLC, and Knott David M Jr all entered Myriad Genetics (NASDAQ:MYGN) positions in the first quarter. These entries were documented through regulatory filings, highlighting strategic allocations among multiple firms.

The entry of new positions complements existing holdings by D. E. Shaw & Co. Inc. and Connor Clark & Lunn Investment Management Ltd., collectively reflecting ongoing adjustments in share distribution. This activity demonstrates how quarterly filings provide transparency into significant shifts in and engagement.

How do research firm ratings affect Myriad Genetics perception?

Myriad Genetics has been monitored by research firms providing assessments that influence market visibility. Scotiabank revised the company rating from sector-outperform to sector-perform, while Piper Sandler lowered target values for the stock.

Overall, the distribution of research assessments shows four firms assigning ratings, nine assigning Hold, and one assigning Sell. These evaluations shape broader market understanding without directing actions. Target adjustments reflect observed market performance and developments specific to MYGN.

What are the largest quarterly share additions recently?

1. E. Shaw & Co. Inc. recorded the largest quarterly increase in MYGN shares during the fourth quarter. The firm acquired an additional block, significantly increasing total holdings. Connor Clark & Lunn Investment Management Ltd. also expanded positions during the first quarter, acquiring a substantial number of shares relative to its existing stake.

Graham Capital Management L.P., Walleye Capital LLC, and Knott David M Jr also contributed to quarterly additions, though with smaller overall volumes. These movements highlight the continued attention MYGN receives from multiple firms across different reporting periods.

How often do firms adjust Myriad Genetics share positions?

Share adjustments for Myriad Genetics (NASDAQ:MYGN) occur quarterly, documented through 13F filings. The first quarter of the year saw multiple entities adding or entering positions, while the fourth quarter recorded additional expansions by D. E. Shaw & Co. Inc.

Regular quarterly adjustments are common for stocks with concentrated. The filings allow transparency into which entities are acquiring or expanding positions, reflecting shifts in allocation strategies without implying recommendations.

Which firms reduced Myriad Genetics positions recently?

Although the majority of activity involved additions, some firms reduced exposure to MYGN during certain periods. Reductions occurred in the context of portfolio management or reallocation, with changes carefully documented in quarterly reports.

Nuveen LLC, for example, engaged with MYGN primarily through new positioning, while other firms adjusted pre-existing stakes. This balance between increases and reductions maintains overall stability in MYGN’s market profile and contributes to observed trading dynamics.

How does Myriad Genetics share concentration affect activity?

High concentration of Myriad Genetics (NASDAQ:MYGN) shares among large firms creates a market environment dominated by structured participants. Over ninety-nine percent of shares are held by a small number of entities, limiting distribution among smaller traders.

This structure ensures that adjustments by large stakeholders can influence observed market activity, including trading volume patterns and share availability. New positions or expansions are tracked closely in regulatory filings, offering insight into the broader stock environment.